Bottom line
FBDIX vs PBE: the short answer
FBDIX (Franklin Biotechnology Discovery Fund) and PBE (Invesco Biotechnology & Genome ETF) are both mutual funds.
But FBDIX is far broader, holding 126 positions to 33 for PBE, so beyond the top names it adds exposure PBE doesn't have.
PBE is cheaper at 0.59% vs 1.01% — a difference of $42 a year per $10,000 invested.
Over five years, FBDIX returned +5.0% a year vs +3.4% for PBE.
FBDIX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
FBDIX vs PBE side by side
| FBDIX | PBE | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Franklin Templeton | Invesco |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 1.01% | 0.59% |
| Annual cost per $10k | $101 | $59 |
| 10-yr cost on $10k (prospectus) | $1,728 | $738 |
| Max front load | 5.5% | None |
| 12b-1 fee | 0.25% | — |
| 1-yr return | +43.9% | +24.7% |
| 5-yr return (annualized) | +5.0% | +3.4% |
| 10-yr return (annualized) | +6.4% | +5.2% |
| Best quarter | +29.5% | +25.3% |
| Worst quarter | −24.5% | −24.3% |
| Net assets (fund) | $1.2B | $281.9M |
| Number of holdings | 126 | 33 |
| Portfolio turnover | 38% | 103% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FBDIX | PBE | Difference |
|---|---|---|---|
| 2025 | +52.3% | +24.7% | +27.6% |
| 2024 | +4.0% | +1.1% | +2.9% |
| 2023 | +18.4% | +3.7% | +14.7% |
| 2022 | −12.7% | −10.8% | −1.9% |
| 2021 | −17.7% | +1.6% | −19.3% |
| 2020 | +29.9% | +25.5% | +4.4% |
| 2019 | +34.8% | +18.3% | +16.6% |
| 2018 | −15.7% | +0.2% | −16.0% |
| 2017 | +18.8% | +22.4% | −3.6% |
| 2016 | −17.2% | −23.0% | +5.9% |
Source: Fund prospectus bar charts
Holdings overlap
5 of FBDIX's top 25 holdings also appear in PBE's top 25.
| Holding | FBDIX | PBE |
|---|---|---|
| Amgen, Inc. | 4.39% | 5.22% |
| Gilead Sciences, Inc. | 3.86% | 4.43% |
| Regeneron Pharmaceuticals, Inc. | 3.77% | 5.47% |
| Vertex Pharmaceuticals, Inc. | 3.54% | 4.99% |
| Neurocrine Biosciences, Inc. | 1.82% | 2.66% |
Source: SEC Form N-PORT
FBDIX top 10
- Jazz Pharmaceuticals plc — 5.66%
- Amgen, Inc. — 4.39%
- Gilead Sciences, Inc. — 3.86%
- Regeneron Pharmaceuticals, Inc. — 3.77%
- Argenx SE — 3.62%
- Vertex Pharmaceuticals, Inc. — 3.54%
- Franklin Institutional U.S. Government Money Market Fund — 3.18%
- Revolution Medicines, Inc. — 3.01%
- Guardant Health, Inc. — 2.76%
- Ascendis Pharma A/S — 2.56%
PBE top 10
- Invesco Private Prime Fund — 12.89%
- Regeneron Pharmaceuticals, Inc. — 5.47%
- Amgen Inc. — 5.22%
- CareDx, Inc. — 5.04%
- Vertex Pharmaceuticals Inc. — 4.99%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Biogen Inc. — 4.79%
- Gilead Sciences, Inc. — 4.43%
- United Therapeutics Corp. — 4.08%
FAQ
What is the difference between FBDIX and PBE?
Which is cheaper, FBDIX or PBE?
Should I own both FBDIX and PBE?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.